Short- and long-term effects of beta-blockers on symptoms of anxiety and depression in patients with myocardial infarction and preserved left ventricular function: a pre-specified quality of life sub-study from the REDUCE-AMI trial
Authors' conclusion
Beta-blocker treatment led to a modest increase in depressive symptoms among MI patients with preserved LVEF.
Study context
- Population
- Patients with myocardial infarction (MI) and preserved left ventricular ejection fraction (LVEF)
- Participants
- 806 patients
- Comparison
- Beta-blocker vs no beta-blocker
- Primary endpoint
- Self-reported symptoms of anxiety and depression (Hospital Anxiety and Depression Scale)
- Follow-up
- 6-10 weeks and 12-14 months after MI
Methodological detailspre-specified sub-study, parallel-group, open-label, registry-based, Enrolment August 2018 through June 2022
- Pre-specified sub-study
- Parallel-group
- Open-label
- Registry-based
- Enrolment August 2018 through June 2022
Primary result
As reported in the abstract
Depressive symptoms
β
0.48
95% CI 09–0.86; P = 0.015
follow-up 1
β
0.41
95% CI 0.01–0.81; P = 0.047
follow-up 2
Further findings
Baseline anxiety and depression
- Possible cases of anxiety (mean 5.6; SD 3.9)
- 27%
- Possible cases of depression (mean 3.9; SD 3.2)
- 14%
Original publication
Short- and long-term effects of beta-blockers on symptoms of anxiety and depression in patients with myocardial infarction and preserved left ventricular function: a pre-specified quality of life sub-study from the REDUCE-AMI trial. Eur Heart J Acute Cardiovasc Care. Published 3 October 2024. doi:10.
Summarised from the published abstract; every number is checked against it